

MEDICAL EVENT HIGHLIGHT

A New Benchmark in Hematology Collaboration Across the MENA Region

REGIONAL LEADERS GATHER TO SHAPE THE FUTURE OF HEMATOLOGICAL CARE

On May 9–10, 2025, the vibrant city of Cairo, Egypt, hosted the much anticipated HemaCompass – 1st Hematology MENA Summit. The event united prominent hematology experts, clinical pharmacists, and leading physicians from across the Middle East and North Africa, fostering an unprecedented opportunity for region-wide knowledge exchange and networking.

The summit, set against the historic backdrop of Cairo and the majestic Nile at the Four Seasons Hotel at First Residence, focused on bridging science with local clinical practice. Through dynamic workshops, interactive panels, and peer case discussions, the summit emphasized tailored patient management strategies and region-specific solutions.

DAY 1

Lymphoma Deep Dive

9th of May 2025



Commenced with a series of lectures and case discussions traversing the spectrum of lymphoma management, the latest in BTK inhibitor therapy, and quality-of-life considerations for patients with Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. An engaging "A Battle of BTKi" segment stimulated expert debate, and dedicated panels moderated by regional thought leaders offered practical insights on challenging cases.

DAY 2

CLL Innovation & Expert Exchange

10th of May 2025



The final day centered on chronic lymphocytic leukemia (CLL), from diagnostics and pitfalls to the forefront of targeted therapies and resistance mechanisms. Sessions such as "BTK Inhibition in CLL: A Pathway to Targeted and Durable Remission" and "Revolutionizing CLL Care: Current Advances and Emerging Therapies" delivered both foundational and updates. Insightful panel discussions and case presentations highlighted the importance of balancing innovation, affordability, and local practice realities.

KEY HIGHLIGHTS & CLINICAL INSIGHTS

■ Precision Medicine:

The summit underscored the critical role of molecular diagnostics and individualized therapy. Faculty stressed that rapid genetic testing and the adoption of mutation-specific treatment for conditions such as AML and CLL are essential to improving outcomes, mirroring recent calls to action in the region.

■ Expert-Led Content:

Educational sessions navigated the contemporary therapeutic landscape, with hands-on reviews of BTK inhibitors drawing on comparative evidence for their use in both lymphoma and CLL, as well as the latest safety monitoring strategies.

■ Collaborative Spirit:

With participation from regional societies and global partners, the summit reflected a growing consensus for harmonized guidelines and unified standards of care for hematological malignancies.



LEADERSHIP REMARKS



HemaCompass has set a new precedent for interconnectedness and shared ambition in MENA hematology. The open exchange of local experiences, coupled with medical science, will accelerate our progress toward world-class, patient-centered care.

Dr. Asma Al Olama

President, Emirates Society of Hematology
Consultant Hematologist, Dubai Hospital,
UAE



The HemaCompass Summit provided an invaluable platform to gain insights into the latest advancements in diagnostics and therapeutic strategies. The collective emphasis on precision medicine and the development of harmonized guidelines holds significant promise for optimizing hematology care and improving patient outcomes across our region.

Prof. Mohammed Yassin

Consultant Hematologist
National Center for Cancer Care and
Research – Qatar



Participating in the summit provided me with a unique opportunity to network with peers and global leaders alike. The focus on BTK inhibitors and complex case management in lymphoma and CLL was both practical and immediately relevant to my patient population

Dr. Hadeel Ammar

Consultant Hematologist
Dubai Hospital, UAE

CONCLUSION

The summit concluded with an expressed commitment to sustaining the momentum of precision medicine and multidisciplinary teamwork, positioning the MENA region as a leader in innovative hematology care.

ENDORSED BY



ORGANIZED BY

POWERED BY